Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure

Cardiovascular Research

Volumn 113, Issue 6, 2017, Pages 633-643

  Li, Jihe ^a   Yousefi, Keyvan ^a   Ding, Wen ^a   Singh, Jayanti ^a   Shehadeh, Lina A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Aptamer; Cardiac fibrosis; Cardiac hypertrophy; Heart failure; Osteopontin; TAC

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 3; COLLAGEN TYPE 3 A1; FIBRONECTIN; FIBRONECTIN 1; LUMICAN; NATRIURETIC PEPTIDE A; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; APTAMER; COL3A1 PROTEIN, MOUSE; CYTOKINE; LUM PROTEIN, MOUSE; SPP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; 129 MOUSE; ANIMAL; AORTA; ARTERIAL PRESSURE; C57BL MOUSE; CARDIAC MUSCLE; DEFICIENCY; DISEASE MODEL; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; KNOCKOUT MOUSE; LIGATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PREVENTION AND CONTROL; SURGERY; TIME FACTOR;

ANIMALS; AORTA; APTAMERS, NUCLEOTIDE; ARTERIAL PRESSURE; COLLAGEN TYPE III; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; LIGATION; LUMICAN; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; OSTEOPONTIN; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85019156068     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx016     Document Type: Article

References (29)

1. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010; 122: 2727-2735.
2. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 2007; 6: 617-635.
3. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J Biol Chem 1995; 270: 28471-28478.
4. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997; 96: 3063-3071.
5. Lorenzen JM, Schauerte C, Hubner A, Kolling M, Martino F, Scherf K, Batkai S, Zimmer K, Foinquinos A, Kaucsar T, Fiedler J, Kumarswamy R, Bang C, Hartmann D, Gupta SK, Kielstein J, Jungmann A, Katus HA, Weidemann F, Muller OJ, Haller H, Thum T. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur Heart J 2015; 36: 2184-2196.
6. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996; 98: 2218-2227.
7. Renault MA, Robbesyn F, Reant P, Douin V, Daret D, Allieres C, Belloc I, Couffinhal T, Arnal JF, Klingel K, Desgranges C, Dos Santos P, Charpentier F, Gadeau AP. Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy. Circ Heart Fail 2010; 3: 431-439.
8. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001; 88: 1080-1087.
9. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, Law RE, Nicholas S, Ross RS, Hsueh WA. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004; 43: 1698-1705.
10. Lorenzen JM, Schauerte C, Hubner A, Kolling M, Martino F, Scherf K, Batkai S, Zimmer K, Foinquinos A, Kaucsar T, Fiedler J, Kumarswamy R, Bang C, Hartmann D, Gupta SK, Kielstein J, Jungmann A, Katus HA, Weidemann F, Muller OJ, Haller H, Thum T. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur Heart J 2015; 36: 2184-2196.
11. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-291.
12. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006; 5: 2957-2962.
13. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9: 537-550.
14. Banerjee J, Nilsen-Hamilton M. Aptamers: multifunctional molecules for biomedical research. J Mol Med (Berl) 2013; 91: 1333-1342.
15. Thiel KW, Giangrande PH. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 2009; 19: 209-222.
16. Berezhnoy A, Castro I, Levay A, Malek TR, Gilboa E. Aptamer-targeted inhibition of mTOR in t cells enhances antitumor immunity. J Clin Invest 2013; 124: 188-197.
17. Berezhnoy A, Brenneman R, Bajgelman M, Seales D, Gilboa E. Thermal stability of siRNA modulates aptamer-conjugated siRNA inhibition. Mol Ther Nucleic Acids 2012; 1: e51.
18. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010; 465: 227-230.
19. Liu N, Zhou C, Zhao J, Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a muc1 aptamer-let-7i chimera. Cancer Invest 2012; 30: 577-582.
20. Dai F, Zhang Y, Zhu X, Shan N, Chen Y. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol 2012; 7: 217-225.
21. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17: 153-161.
22. Talbot LJ, Mi Z, Bhattacharya SD, Kim V, Guo H, Kuo PC. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 2011; 150: 224-230.
23. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 1468-1478.
24. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 2004; 44: 826-831.
25. Zhao M, Chow A, Powers J, Fajardo G, Bernstein D. Microarray analysis of gene expression after transverse aortic constriction in mice. Physiol Genomics 2004; 19: 93-105.
26. Emde B, Heinen A, Godecke A, Bottermann K. Wheat germ agglutinin staining as a suitable method for detection and quantification of fibrosis in cardiac tissue after myocardial infarction. Eur J Histochem 2014; 58: 2448.
27. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. ETA-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
28. Zhao H, Wang W, Zhang J, Liang T, Fan GP, Wang ZW, Zhang PD, Wang X. Inhibition of osteopontin reduce the cardiac myofibrosis in dilated cardiomyopathy via focal adhesion kinase mediated signaling pathway. Am J Transl Res. 2016; 8: 3645-3655.
29. Fan D, Takawale A, Basu R, Patel V, Lee J, Kandalam V, Wang X, Oudit GY, Kassiri Z. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc Res 2014; 103: 268-280.